Management of Crohn’s Disease: Advances in Mesenchymal Stromal Cell Therapy - Abstract
Crohn’s disease (CD) is a chronic intestinal inflammatory disorder that is hypothesized to develop mainly due to a dysregulated immune response and dysbiosis in genetically predisposed individuals. Current treatment of CD with available agents like immunomodulators and biological drugs is poor and associated with various adverse effects. Mesenchymal stromal cells (MSC) with their immunomodulatory and tissue regenerative properties have shown great promise in the management of treatment-refractory CD patients with good safety profile.